Edition:
India

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

36.18USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$36.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
114,352
52-wk High
$40.90
52-wk Low
$5.35

Latest Key Developments (Source: Significant Developments)

Uniqure NV Files For Potential Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Friday, 15 Jun 2018 

June 14 (Reuters) - Uniqure NV ::UNIQURE NV FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

uniQure Announces Proposed Public Offering
Wednesday, 2 May 2018 

May 1 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES PROPOSED PUBLIC OFFERING.UNIQURE NV - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 4 MILLION OF ITS ORDINARY SHARES.  Full Article

Uniqure Q1 Revenue $3.5 Mln Vs I/B/E/S View $2.8 Mln
Monday, 30 Apr 2018 

April 30 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS.Q1 LOSS PER SHARE $0.59.Q1 REVENUE $3.5 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.74 -- THOMSON REUTERS I/B/E/S.IND FILING FOR AMT-130 IN HUNTINGTON'S DISEASE EXPECTED IN SECOND HALF OF 2018.PATIENT ENROLLMENT EXPECTED TO BEGIN AHEAD OF SCHEDULE IN DOSE-CONFIRMATION STUDY FOR AMT-061.AMT-061 PIVOTAL STUDY ON TRACK TO COMMENCE IN Q3 OF 2018.CURRENTLY EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO EARLY 2020.  Full Article

Uniqure Says As Of Dec 31 Co Had $159 Mln In Cash & Cash Equivalents
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Uniqure Nv ::UNIQURE PROVIDES YEAR-END 2017 CORPORATE UPDATE AND OUTLINES NEAR-TERM OBJECTIVES TO FURTHER DRIVE SHAREHOLDER VALUE.UNIQURE - AS OF DEC 31, 2017, CO HAD ABOUT $159 MILLION IN CASH & CASH EQUIVALENTS; EXPECTS CASH ON HAND SUFFICIENT TO FUND OPERATIONS INTO 2020.UNIQURE NV - INTENDS TO INITIATE GLOBAL, PIVOTAL PROGRAM FOR AMT-061 IN HEMOPHILIA B DURING Q3 2018.UNIQURE NV - AMENDMENT TO EXISTING INVESTIGATIONAL NEW DRUG (IND) APPLICATION EXPECTED FOR AMT-061 TO BE SUBMITTED TO FDA IN Q1 2018.  Full Article

UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES UPDATED, LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 IN PATIENTS WITH SEVERE HEMOPHILIA B.UNIQURE -AAV5-BASED AMT-060 REMAINS SAFE,WELL-TOLERATED WITH UPTO 2 YEARS OF FOLLOW-UP,WITH NO NEW SERIOUS ADVERSE EVENTS,NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Q3 loss per share $0.40
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Uniqure Nv ::Uniqure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

UniQure reports Q3 loss $0.40/shr
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - UniQure Nv :UniQure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Uniqure NV says ‍priced its underwritten public offering of 5 mln shares at $18.25 per share​
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Uniqure NV -:Uniqure announces pricing of its public offering.Uniqure NV says ‍announced pricing of its underwritten public offering of 5 million of its ordinary shares at a public offering price of $18.25 per share​.  Full Article

Uniqure announces proposed public offering
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Uniqure NV ::Uniqure announces proposed public offering.Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares.  Full Article

uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - uniQure Nv :uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua).  Full Article

BRIEF-Uniqure Receives Orphan Medicinal Product Designation In Europe For Amt-130 In Huntington’S Disease

* UNIQURE RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR AMT-130 IN HUNTINGTON’S DISEASE Source text for Eikon: Further company coverage: